Mylan's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Mylan (MYL)

Q1 2012 Earnings Call

April 26, 2012 10:00 am ET

Executives

Kris King -

Heather Bresch - Chief Executive Officer and Director

John D. Sheehan - Chief Financial Officer and Executive Vice President

Rajiv Malik - President

Analysts

Douglas D. Tsao - Barclays Capital, Research Division

Christopher Schott - JP Morgan Chase & Co, Research Division

Elliot Wilbur - Needham & Company, LLC, Research Division

David Risinger - Morgan Stanley, Research Division

Marc Goodman - UBS Investment Bank, Research Division

Jami Rubin - Goldman Sachs Group Inc., Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

John T. Boris - Citigroup Inc, Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division

Gary Nachman - Susquehanna Financial Group, LLLP, Research Division

Michael Faerm - Crédit Suisse AG, Research Division

Randall Stanicky - Canaccord Genuity, Research Division

Presentation

Operator

Welcome to Mylan's First Quarter Earnings Conference Call and Webcast. Hosting the call today from Mylan is Ms. Kris King, Vice President, Global Investor Relations. Today's call is being recorded and will be available for replay beginning at 1 p.m. Eastern standard time. The dial in number is (800) 585-8367, or (404) 537-3406 for international callers, with pin number 70819215. [Operator Instructions] It is now my pleasure to turn the floor over to Kris King, you may begin.

Kris King

Thank you, Beverly. Good morning, everyone. Welcome to Mylan's first quarter 2012 earnings call. Joining me for today's call are Mylan's CEO, Heather Bresch; President, Rajiv Malik; Chief Operating Officer, Hal Korman; and Executive Vice President and Chief Financial Officer, John Sheehan.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Will Allergan's Deal With Tribe Hold Up?

Trading Mylan: Look Out for This Key Level

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids